遗传检测指导癫痫治疗管理:一项国际临床实践研究
这项回顾性横断面研究纳入418例接受多基因panel检测并检出致病/可能致病变异的癫痫患者,49.8%的患者因遗传诊断改变了临床管理,通常在收到结果后3个月内。在有随访信息的167例患者中,74.9%报告积极结局,64.7%报告癫痫发作减少或消失。
要点
- 418例癫痫患者中,49.8%因遗传诊断改变临床管理,81.7%在3个月内完成。
- 常见管理改变包括加用新药21.7%、启动用药14.2%、转诊专科13.4%。
- 167例有随访者中,74.9%报告积极结局,64.7%发作减少或消失。
核心结论
- 这项横断面研究提示,对癫痫患者进行遗传检测可能与临床决策和患者结局改善有实质性关联。
研究设计与样本
- 回顾性横断面研究,纳入2016年3月18日至2020年8月3日转诊接受多基因panel检测、检出致病/可能致病变异的癫痫患者418例。
- 研究设置包括一家商业遗传检测实验室和多中心临床实践,所有医疗保健专业人员填写病例报告表。
主要发现
- 418例患者检测时中位年龄4岁(IQR 1-10),范围0至52岁,女性53.8%(n=225)。
- 从开具遗传检测到病例报告表完成的平均(SD)时间为595(368)天,范围27至1673天。
- 208例(49.8%)患者遗传诊断与临床管理改变相关,其中81.7%在收到结果后3个月内发生。
- 常见管理改变:加用新药78例(21.7%)、启动用药51例(14.2%)、转诊专科48例(13.4%)、警惕亚临床或神经系统外疾病特征46例(12.8%)、停用药物42例(11.7%)。
- 167例有随访临床信息者(平均随访584(365)天)中,125例(74.9%)报告积极结局,108例(64.7%)发作减少或消失,37例(22.2%)其他临床体征严重程度下降,11例(6.6%)药物不良反应减少;少数报告结局恶化,包括病情下降20例(12.0%)、发作频率增加6例(3.6%)、药物不良反应3例(1.8%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is currently unknown how often and in which ways a genetic diagnosis given to a patient with epilepsy is associated with clinical management and outcomes. OBJECTIVE: To evaluate how genetic diagnoses in patients with epilepsy are associated with clinical management and outcomes. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cross-sectional study of patients referred for multigene panel testing between March 18, 2016, and August 3, 2020, with outcomes reported between May and November 2020. The study setting included a commercial genetic testing laboratory and multicenter clinical practices. Patients with epilepsy, regardless of sociodemographic features, who received a pathogenic/likely pathogenic (P/LP) variant were included in the study. Case report forms were completed by all health care professionals. EXPOSURES: Genetic test results. MAIN OUTCOMES AND MEASURES: Clinical management changes after a genetic diagnosis (ie, 1 P/LP variant in autosomal dominant and X-linked diseases; 2 P/LP variants in autosomal recessive diseases) and subsequent patient outcomes as reported by health care professionals on case report forms. RESULTS: Among 418 patients, median (IQR) age at the time of testing was 4 (1-10) years, with an age range of 0 to 52 years, and 53.8% (n = 225) were female individuals. The mean (SD) time from a genetic test order to case report form completion was 595 (368) days (range, 27-1673 days). A genetic diagnosis was associated with changes in clinical management for 208 patients (49.8%) and usually (81.7% of the time) within 3 months of receiving the result. The most common clinical management changes were the addition of a new medication (78 [21.7%]), the initiation of medication (51 [14.2%]), the referral of a patient to a specialist (48 [13.4%]), vigilance for subclinical or extraneurological disease features (46 [12.8%]), and the cessation of a medication (42 [11.7%]). Among 167 patients with follow-up clinical information available (mean [SD] time, 584 [365] days), 125 (74.9%) reported positive outcomes, 108 (64.7%) reported reduction or elimination of seizures, 37 (22.2%) had decreases in the severity of other clinical signs, and 11 (6.6%) had reduced medication adverse effects. A few patients reported worsening of outcomes, including a decline in their condition (20 [12.0%]), increased seizure frequency (6 [3.6%]), and adverse medication effects (3 [1.8%]). No clinical management changes were reported for 178 patients (42.6%). CONCLUSIONS AND RELEVANCE: Results of this cross-sectional study suggest that genetic testing of individuals with epilepsy may be materially associated with clinical decision-making and improved patient outcomes.
引用
- McKnight D, Morales A, Hatchell KE, et al. Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice. JAMA Neurol. 2022. PMID: 36315135. doi:10.1001/jamaneurol.2022.3651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。